Clinical indications for thrombopoietin and thrombopoietin-receptor agonists

Transfusion Medicine and Hemotherapy

Volumn 40, Issue 5, 2013, Pages 319-325

  Wörmann, Bernhard ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Gesellschaft für medizinische Innovation Hämatologie und Onkologie mbH   (Germany)

Author keywords

Cirrhosis; Eltrombopag; ITP; Myelodysplastic syndrome; Romiplostim

Indexed keywords

AZACITIDINE; BOCEPREVIR; CYTOKINE RECEPTOR AGONIST; DECITABINE; ELTROMBOPAG; GROWTH FACTOR; LENALIDOMIDE; ORPHAN DRUG; PLACEBO; ROMIPLOSTIM; TELAPREVIR; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR;

ANTIVIRAL THERAPY; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; CELL MATURATION; CELL PROLIFERATION; CHRONIC LIVER DISEASE; CLINICAL TRIAL (TOPIC); ELECTIVE SURGERY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LIVER CIRRHOSIS; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; TREATMENT INDICATION;

EID: 84886617137     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000355006     Document Type: Review

References (69)

1. Giaganoudis A, Ehninger G: Thrombozytopenien. www.dgho-onkopedia.org/de/onkopedia/leitlinien/ thrombozytopenien.
2. Schrezenmeier H, Seifried E: Platelet-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be used? Vox Sang 2010;99:1-15.
3. Henseler O, Helden M, Haschberger B, et al.: Bericht zur Meldung nach 21 TFG für die Jahre 2008 und 2009. Bundesgesundheitsbl 2010;53:1089-1103.
4. Kaushansky K: Historical review: megakaryopoiesis and thrombopoiesis. Blood 2008;111:981-986.
5. Deutsch VR, Tomer A: Advances in megakaryocytopoiesis: from bench to bedside. Br J Haematol 2013;161:778-793.
6. Metcalf D: Thrombopoietin: At last. Nature 1994; 369:519-520.
7. de Sauvage FJ, Hass PE, Spencer SD, et al: Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994;369:533-538.
8. Lok S, Kaushansky K, Holly RD, et a.: Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994;369:565-568.
9. Kaushansky K, Lok S, Holly RD, et al: Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994;369:568-571.
10. Bartley TD, Bogenberger J, Hunt P, et al: Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994;77:1117-1124.
11. Sohma Y, Akahori H, Seki N, et al: Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Lett 1994;353:57-61.
12. Foster DC, Sprecher CA, Grant FJ et al: Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization. Proc Natl Acad Sci U S A 1994;91:13023-13027.
13. Kuter DJ, Beeler DL, Rosenberg RD: The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A 1994;91:11104-11108.
14. Geddis AE, Linden HM, Kaushansky K: Thrombopoietin: A pan-hematopoietic cytokine. Cytokine Growth Factor Rev 2002;13:61-73.
15. Congenital Amegakaryocytic Thrombocytopenia. OMIM 604498. http://omim.org/entry/604498.
16. Ihara K, Ishii E, Eguchi M, Takada H, Suminoe A, Good RA, Hara T: Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci USA 1999; 96:3132-3136.
17. Ballmaier M, Germeshausen M, Schulze H, et al: c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001;97: 139-146.
18. King S, Germeshausen M, Strauss G, Welte K, Ballmaier M: Congenital amegakaryocytic thrombocytopenia: A retrospective clinical analysis of 20 patients. Br J Haematol 2005;131:636-644.
19. Thrombocythemia-1. OMIM 600044.0001. http:// omim.org/entry/600044#0001.
20. Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC: An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet 1998;18:49-52.
21. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al: Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with Cancer. Ann Intern Med 1997;126:673-681.
22. Kuter DJ, Goodnough LT, Romo J, et al: Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 2001;98:1339-1345.
23. Fanucchi M, Glaspy J, Crawford J, et al: Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997;336:404-409.
24. Vadhan-Raj S: Clinical experience with recombinant human thrombopoietin in chemotherapyinduced thrombocytopenia. Semin Hematol 2000; 37(suppl4):S28-S34.
25. Kuter DJ, Begley CG: Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002;100:3457-3469.
26. Li J, Yang C, Xia Y, et al: Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98:3241-3248.
27. Stasi R, Bosworth J, Rhodes E, et al: Thrombopoietic agents. Blood Rev 2010;24:179-190.
28. Basciano PA, Bussel JB: Thrombopoietin-receptor agonists. Curr Opin Hematol 2012;19:392-398.
29. Wang B, Nichol JL, Sullivan JT: Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004;76:628-638.
30. Jenkins JM, Williams D, Deng Y, et al: Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007;109: 4739-4741.
31. Matzdorff A, Giagounidis A, Müller-Beißenhirtz H: Immunthrombozytopenie. www.dgho-onkopedia. org/de/onkopedia/leitlinien/immunthrombozytopenieitp.
32. Cines DB, Bussel JB, Liebman HA, Prak ETL: The ITP syndrome: pathogenic and clinical diversity. Blood 2009;113:6511-6221.
33. Rodeghiero F, Stasi R, Gernsheimer T, et al: Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children: Report from an international working group. Blood 2009;113: 2386-2393.
34. Provan D, Stasi R, Newland AC, Blanchette VS, et al: International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-186.
35. Imbach P, Crowther M: Thrombopoietin-receptor agonists in primary immune thrombocytopenia. N Engl J Med 2011;365:734-741
36. Nomura S, Dan K, Hotta T, et al: Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002;100:728-730.
37. Bussel JB, Cheng G, Saleh MN, et al: Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-2247.
38. Bussel JB, Provan D, Shamsi T, et al: Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomised, double-blind, placebocontrolled trial. Lancet 2009;373:641-648.
39. Cheng G, Saleh MN, Marcher C, et al: Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study. Lancet 2011;377:393-402.
40. Kuter DJ, Bussel JB, Lyons RM, et al: Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet 2008;371:395-403.
41. Kuter DJ, Rummel M, Boccia R, et al: Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010;363:1889-1899.
42. Altomare I, Wasser J, Pullarkat V: Bleeding and mortality outcomes in ITP clinical trials: A review of thrombpoietin mimetics data. Am J Hematol 2012;87:984-987.
43. Khellaf M, Viallard JF, Hamidou M: Switching from romiplostim to eltrombobag or vice versa for immune thrombocytopenia: efficacy and safety in 46 patients patients. 54th ASH Annual Meeting, December 8-11, 2012, Abstract 4651.
44. Piccin A, Amaddii G, Natolino F, et al: Idiopathic thrombocytopenia purpura resistant to eltrombopag, but cured with romiplostim. Blood Transfus 2013;17:1-2.
45. Iuliano F, Perricelli A, Iuliano E, et al: Platelet kinetic study (PKS) may early identify a subset of patients with immune thrombocytopenia (ITP) probably cured by romiplostim. Two years followup. 54th ASH Annual Meeting, December 8-11, 2012, Abstract 1099.
46. Neunert C, Lim W, Crowther M, et al: American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117:4190-207.
47. Hofmann WK, Platzbecker U, Gotze K, et al: Myelodysplastische Syndrome. www.dgho-onkopedia. org/de/onkopedia/leitlinien/mds.
48. Kantarjian H, Giles F, List A, et al: The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007;109:1705-1714.
49. Kantarjian H, Fenaux P, Sekeres MA, et al: Safety and efficacy of romiplostim in patients with lowerrisk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010;28:437-444.
50. Kantarjian H, Giles FJ, Greenberg PL, et al: Phase 2 study of romiplostim in patients with low-or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010;116:3163-3170.
51. Wang ES, Lyons RM, Larson RA, et al: A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol 2012;25:71-83.
52. Greenberg PL, Guillermo Garcia-Manero G, Moore M, et al: A randomized controlled trial of romiplostim in patients with low-or intermediaterisk myelodysplastic syndrome receiving decitabine. Leuk Lymphoma 2013;54:321-328.
53. Gardner K, Mathe S, Sahu S: Leukaemic transformation with romiplostim. Br J Haematol 2012;158: 153.
54. Greinacher A, Kiefel V, Kluter H, et al: Thrombozytentransfusion. www.dgho-onkopedia.org/de/ onkopedia/leitlinien/thrombozytentransfusion.
55. Wandt H, Schaefer-Eckart K, Wendelin K, et al: Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: An open-label, multicentre, randomised study. Lancet 2012;380:1309-1316.
56. Stanworth SJ, Estcourt LJ, Powter G, et al: A noprophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med 2013;368:1171-1780.
57. Levy B, Arnason JE, Bussel JB: The use of secondgeneration thrombopoietic agents for chemotherapy-induced thrombocytopenia. Curr Opin Oncol 2008;20:690-696.
58. Schiffer CA, Miller K, Larson RA, et al: A double blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000;95:2530-2535.
59. Archimbaud E, Ottmann OG, Yin JA, et al: A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEGrHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999;94:3694-3701.
60. Kellum A, Jagiello-Gruszfeld A, Bondarenko IN, et al: A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carbopolatin/ paclitaxel for advanced solid tumors. Curr Med Res Opin 2010;26:2339-2346.
61. Hayes S, Mudd PN Jr, Ouellet D, et al: Population PD/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia. Cancer Chemother Pharmacol 2013;71:1507-1520.
62. Townsley DM, Desmond R, Dunbar CE, Young NS: Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes. Int J Hematol 2013;98:48-55.
63. Schrezenmeier H, Brummendorf TH, Linkesch W, et al.: Aplastische Anamie-Diagnostik und Therapie der erworbenen Aplastischen Anamie. www. dgho-onkopedia.org/de/onkopedia/leitlinien/aplastischeanaemie-diagnostik-und-therapie-der.
64. Olnes MJ, Scheinberg P, Calvo KR, et al: Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 2012;367:11-19.
65. Trautman K, Jakob C, von Grunhagen U, et al: Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and Diamond-Blackfan anaemia. Thromb Haemost 2012; 108:397-398.
66. Qamar AA, Grace ND, Groszmann RJ, et al: Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol 2009;7:689-695.
67. Afdhal N, McHutchison J, Brown R, et al: Thrombocytopenia associated with chronic liver disease. J Hepatol 2008;48:1000-1007.
68. McHutchison JG, Dusheiko G, Shiffman ML, et al: Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227-2236.
69. Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, Jeffers L, McHutchison J, Chen PJ, Han KH, Campbell F, Hyde D, Brainsky A, Theodore D; ELEVATE Study Group: Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012;367: 716-724.